Kazia Therapeutics Ltd - Intends to consider all available options to address shortcomings and restore compliance with Nasdaq rules

Kazia Therapeutics Ltd - Intends to consider all available options to address shortcomings and restore compliance with Nasdaq rules

Zhitong FinanceMay 24 02:43

Express News | Kazia Therapeutics Ltd - Intends to Consider All Available Options to Resolve Deficiency and Regain Compliance With Nasdaq Rule

BreakingsMay 24 02:43

Kazia Granted 180-Day Extension by Nasdaq to Meet the Minimum Bid Price Requirement

SYDNEY, May 23, 2024 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA) (Kazia or the company) received a letter on May 22, 2024 from Nasdaq notifying the Company that, while the Company has n

PR NewswireMay 24 02:41

Kazia Therapeutics Says Nasdaq Determined That Company Is Eligible For Additional 180 Calendar Day Period, Or Until November 18, 2024 To Regain Compliance

On May 22, 2024, the Company received a letter from Nasdaq notifying the Company that, while the Company has not regained compliance with the Minimum Bid Price Requirement, Nasdaq has determined that

BenzingaMay 23 19:14

12 Health Care Stocks Moving In Tuesday's Pre-Market Session

GainersBiodexa Pharmaceuticals (NASDAQ:BDRX) shares increased by 67.7% to $2.13 during Tuesday's pre-market session. The market value of their outstanding shares is at $9.3 million. Durect (NASDAQ:DRR

BenzingaMay 21 20:06

Kazia Therapeutics Shares Are Trading Lower. The Company Announced the Completion of the EVT801 Phase 1 Clinical Trial.

Kazia Therapeutics Shares Are Trading Lower. The Company Announced the Completion of the EVT801 Phase 1 Clinical Trial.

BenzingaMay 2 00:08